Quarterly results · VAISHALI
VAISHALI PHARMA LIMITED reported revenue of ₹31.1 cr and net profit of -₹4.29 cr in Q4 FY25 (quarter ended 31 Mar 2025). Below is the full quarter-wise results table with revenue, operating profit, margins, tax, EPS and annual history — updated automatically from exchange filings.
| Quarter | Q4 FY25 |
|---|---|
| Quarter ended | 31 Mar 2025 |
| Revenue | ₹31.1 cr |
| Revenue YoY | — |
| Operating profit | ₹0.13 cr |
| Operating margin | 0.4% |
| Net profit | -₹4.29 cr |
| Net profit YoY | — |
| Net profit QoQ | -397.6% |
| Net margin | -13.8% |
| Basic EPS | — |
| TTM revenue | — |
| TTM net profit | — |
| TTM net margin | — |
VAISHALI PHARMA LIMITED (VAISHALI) has reported its Q4 FY25 results for the quarter ended 2025-03-31. The company posted revenue of ₹31.1 cr and a net profit of -₹4.29 cr, translating into earnings per share of —.
Operating profit for the quarter stood at ₹0.13 cr, an operating margin of 0.4%.
Revenue
₹31.1 cr
— YoY
Net profit
-₹4.29 cr
— YoY
Operating profit
₹0.13 cr
— YoY
EPS
—
— YoY
| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|---|---|---|---|---|---|---|---|
| Q4 FY252025-03-31 | ₹31.1 cr | ₹0.13 cr | -₹4.29 cr | 0.4% | -13.8% | — | — | -397.6% |
| Q3 FY252024-12-31 | ₹27.91 cr | ₹1.24 cr | ₹1.44 cr | 4.5% | 5.2% | ₹0.98 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
| Particulars | Q4 FY252025-03-31 | Q3 FY252024-12-31 |
|---|---|---|
| Revenue / Sales | ₹31.1 cr | ₹27.91 cr |
| Total expenses | ₹30.97 cr | ₹26.67 cr |
| Gross profit | ₹0.46 cr | ₹4.18 cr |
| Operating profit (EBIT) | ₹0.13 cr | ₹1.24 cr |
| Operating margin | 0.4% | 4.5% |
| Interest cost | ₹0.93 cr | ₹0.38 cr |
| Profit before tax | -₹5.6 cr | ₹1.93 cr |
| Tax expense | -₹1.31 cr | ₹0.49 cr |
| Effective tax rate | 23.4% | 25.2% |
| Net profit (PAT) | -₹4.29 cr | ₹1.44 cr |
| Net profit margin | -13.8% | 5.2% |
| Basic EPS | — | ₹0.98 |
| Diluted EPS | — | ₹0.98 |
| Growth | Q4 FY25 | Q3 FY25 |
|---|---|---|
| Revenue YoY | — | — |
| Revenue QoQ | +11.4% | — |
| Operating profit YoY | — | — |
| Operating profit QoQ | -89.4% | — |
| Net profit YoY | — | — |
| Net profit QoQ | -397.6% | — |
| EPS YoY | — | — |
| EPS QoQ | — | — |
Full-year performance for VAISHALI PHARMA LIMITED, useful for reading each quarter in context.
| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|---|---|---|---|
| Revenue / Sales | ₹105 cr | ₹97.88 cr | ₹81.76 cr | ₹63.82 cr |
| Total expenses | ₹99.11 cr | ₹91.98 cr | ₹75.43 cr | ₹54.85 cr |
| Gross profit | ₹9.63 cr | ₹12.21 cr | ₹7.35 cr | ₹9.15 cr |
| Operating profit (EBIT) | ₹5.64 cr | ₹5.9 cr | ₹6.34 cr | ₹8.97 cr |
| Operating margin | 5.4% | 6.0% | 7.8% | 14.1% |
| Interest cost | ₹1.98 cr | ₹2.07 cr | ₹2.27 cr | ₹2.26 cr |
| Profit before tax | ₹5.39 cr | ₹1.23 cr | ₹0.93 cr | ₹8.85 cr |
| Tax expense | ₹1.36 cr | ₹0.41 cr | ₹0.21 cr | ₹2.24 cr |
| Effective tax rate | 25.2% | 33.3% | 22.4% | 25.4% |
| Net profit (PAT) | ₹4.03 cr | ₹0.82 cr | ₹0.72 cr | ₹6.6 cr |
| Net profit margin | 3.8% | 0.8% | 0.9% | 10.3% |
| Basic EPS | — | — | ₹0.07 | ₹0.63 |
| Diluted EPS | — | — | ₹0.07 | ₹0.59 |
Topline for Q4 FY25 came in at ₹31.1 cr, and ₹27.91 cr in the preceding Q3 FY25 quarter.
On a sequential basis revenue grew +11.4%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹30.97 cr, or 99.6% of revenue.
Net profit of -₹4.29 cr works out to a net margin of -13.8%.
Below the operating line, VAISHALI PHARMA LIMITED reported profit before tax of -₹5.6 cr, a tax charge of -₹1.31 cr (effective rate 23.4%), interest cost of ₹0.93 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹1.44 cr in Q3 FY25 to -₹4.29 cr in Q4 FY25, a change of -397.6%.
On a full-year basis, FY26 revenue was ₹105 cr with net profit of ₹4.03 cr and EPS of —, versus the prior year where revenue grew +7.0% and profit grew +393.2%.
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A single weak quarter matters less than the direction over three to four consecutive quarters.
VAISHALI PHARMA LIMITED has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
No results report published for VAISHALI yet — our desk covers each quarter within minutes of the filing.
In Q4 FY25 (quarter ended 31 Mar 2025), VAISHALI PHARMA LIMITED reported revenue of ₹31.1 cr and net profit of -₹4.29 cr. EPS stood at —.
VAISHALI PHARMA LIMITED posted a net profit margin of -13.8% and an operating margin of 0.4% in Q4 FY25. On a trailing twelve-month basis, revenue is — and net profit —.
VAISHALI PHARMA LIMITED net profit changed -397.6% quarter on quarter, from ₹1.44 cr in Q3 FY25 to -₹4.29 cr in Q4 FY25.
VAISHALI PHARMA LIMITED has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Results coverage for VAISHALI will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the VAISHALI stock page.
For FY26, VAISHALI PHARMA LIMITED reported full-year revenue of ₹105 cr and net profit of ₹4.03 cr, with EPS of —.
Past results dates for VAISHALI will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 12 Sept 2026. For information only, not investment advice.
